QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • ImmunoCellular Therapeutics Ltd. (IMUC) Updates On Clinical Activity And Patient Enrollment For Study Of Brain Cancer Vaccine Candidate 0 comments
    May 9, 2012 5:27 PM | about stocks: IMUC

    ImmunoCellular Therapeutics, a biotech company focused on the development of novel immune-based cancer therapies, today issued an update on clinical trial site activity and patient enrollment for its phase II clinical trial of ICT-107, the company's cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM), the most aggressive malignant primary brain tumor.

    The company reports that it has initiated the trial in 25 sites, and that it expects to enroll approximately 200 or more patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There currently are 189 patients enrolled in the study, with final enrollment expected to be completed by the second quarter of 2012.

    "We are excited with the enrollment progress made in the phase II clinical trial of ICT-107," Manish Singh, Ph.D., president and CEO of ImmunoCellular stated in the press release. "We appreciate the continued support from leading medical centers and oncologists as we move our focus from enrollment to obtaining patient data."

    The phase II trial is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate ICT-107's safety and efficacy as treatment for patients with newly diagnosed GBM.

    The company's phase I clinical study of ICT-107 in GBM demonstrated that 16 newly diagnosed patients who received the vaccine combined with standard of care of surgery, radiation, and chemotherapy had a two-year overall survival of 80 percent and a three-year survival of 55 percent vs. the 26 percent two-year and 16 percent three-year survival based on the historical standard of care treatment alone.

    ImmunoCellular reports that no serious adverse treatment related symptoms were observed in any of the patients.

    For more information visit imuc.com

    The Quality Stocks "Ones to Watch" gotstocks.qualitystocks.net

    Stocks: IMUC
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.